Immunological evaluation of a streptococcal preparation (OK-432) in treatment of bladder carcinoma. 1979

S Kagawa, and K Ogura, and K Kurokawa, and K Uyama

When 21 patients with bladder cancer (transitional cell carcinoma) were given local and systemic injections of a streptococcal preparation, OK-432, tumor regression was observed in 3 cases (14.3%). The marked infiltration of lymphocytes observed on histological examination of regressed tumors suggested that a host-mediated action was involved in the antitumor effect of OK-432.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010844 Picibanil A lyophilized preparation of a low-virulence strain (SU) of Streptococcus pyogenes (S. hemolyticus), inactivated by heating with penicillin G. It has been proposed as a noncytotoxic antineoplastic agent because of its immune system-stimulating activity. NSC-B116209,OK-432,Picibanyl,Streptococcal OK-432,Streptococcal Preparation OK-432,NSC B116209,NSCB116209,OK 432,OK432,Streptococcal OK 432,Streptococcal OK432,Streptococcal Preparation OK 432,Streptococcal Preparation OK432
D001749 Urinary Bladder Neoplasms Tumors or cancer of the URINARY BLADDER. Bladder Cancer,Bladder Neoplasms,Cancer of Bladder,Bladder Tumors,Cancer of the Bladder,Malignant Tumor of Urinary Bladder,Neoplasms, Bladder,Urinary Bladder Cancer,Bladder Cancers,Bladder Neoplasm,Bladder Tumor,Cancer, Bladder,Cancer, Urinary Bladder,Neoplasm, Bladder,Neoplasm, Urinary Bladder,Tumor, Bladder,Tumors, Bladder,Urinary Bladder Neoplasm
D002295 Carcinoma, Transitional Cell A malignant neoplasm derived from TRANSITIONAL EPITHELIAL CELLS, occurring chiefly in the URINARY BLADDER; URETERS; or RENAL PELVIS. Carcinomas, Transitional Cell,Cell Carcinoma, Transitional,Cell Carcinomas, Transitional,Transitional Cell Carcinoma,Transitional Cell Carcinomas
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001688 Biological Products Complex pharmaceutical substances, preparations, or matter derived from organisms usually obtained by biological methods or assay. Biologic,Biologic Drug,Biologic Product,Biological,Biological Drug,Biological Medicine,Biological Product,Biologics,Biopharmaceutical,Natural Product,Natural Products,Biologic Drugs,Biologic Medicines,Biologic Pharmaceuticals,Biologic Products,Biological Drugs,Biological Medicines,Biologicals,Biopharmaceuticals,Products, Biological,Drug, Biologic,Drug, Biological,Drugs, Biologic,Drugs, Biological,Medicine, Biological,Medicines, Biologic,Medicines, Biological,Pharmaceuticals, Biologic,Product, Biologic,Product, Biological,Product, Natural

Related Publications

S Kagawa, and K Ogura, and K Kurokawa, and K Uyama
January 1980, Osaka city medical journal,
S Kagawa, and K Ogura, and K Kurokawa, and K Uyama
November 1992, Hinyokika kiyo. Acta urologica Japonica,
S Kagawa, and K Ogura, and K Kurokawa, and K Uyama
February 1989, Hinyokika kiyo. Acta urologica Japonica,
S Kagawa, and K Ogura, and K Kurokawa, and K Uyama
December 1982, The Keio journal of medicine,
S Kagawa, and K Ogura, and K Kurokawa, and K Uyama
January 1985, The Journal of international medical research,
S Kagawa, and K Ogura, and K Kurokawa, and K Uyama
April 2005, The Journal of dermatological treatment,
S Kagawa, and K Ogura, and K Kurokawa, and K Uyama
March 1980, Nagoya journal of medical science,
S Kagawa, and K Ogura, and K Kurokawa, and K Uyama
January 1990, Biotherapy (Dordrecht, Netherlands),
S Kagawa, and K Ogura, and K Kurokawa, and K Uyama
March 2003, The Annals of otology, rhinology, and laryngology,
S Kagawa, and K Ogura, and K Kurokawa, and K Uyama
January 1999, Anticancer research,
Copied contents to your clipboard!